Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Replicating human glycosylation

Although fungal systems are less costly and more efficient at producing proteins than mammalian systems, they fail to recreate the complex human glycosylations that are often necessary for the biological activity of protein therapeutics. Enter GlycoFi Inc., which has been able to engineer yeast and other fungal expression

Read the full 480 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE